Evaluation Using Computed Tomography Angiography (CTA) to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE) (ELUCIDATE))
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00580008|
Recruitment Status : Completed
First Posted : December 24, 2007
Last Update Posted : April 21, 2016
|Condition or disease|
|Arteriosclerosis of Coronary Artery Bypass Graft Coronary Artery Disease|
Patients who have bypass surgery with using vein grafts from their legs (saphenous veins) have a very high risk of developing blockages in the grafts. It has been shown in previous studies that the progression of disease in vein grafts is very quick and can result in chest pain, heart attacks or death. In the past, evaluation of the grafts was possible with heart catheterization only. The technique of CT scan is currently considered an effective way to look at vein grafts as well as the arteries around the heart to identify blockages.
Certain blood proteins have been associated with rapid progression of vein graft blockages. Our purpose is to not only to identify blockages at different stages after bypass surgery, but to investigate the causes of the rapid progression of the disease, including clinical history, risk factors and the blood proteins.
|Study Type :||Observational|
|Actual Enrollment :||178 participants|
|Official Title:||Evaluation Using CTA to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
- Morphological characteristics of vein grafts [ Time Frame: two years ]To identify the presence of and morphological characteristics of vein graft disease in patients at 1 and 2 years post bypass surgery.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00580008
|United States, Michigan|
|William Beaumont Hospital|
|Royal Oak, Michigan, United States, 48073|
|Principal Investigator:||Robert Safian, MD||William Beaumont Hospitals|
|Principal Investigator:||Kavitha Chinnaiyan, MD||William Beaumont Hospitals|
|Principal Investigator:||Gil Raff, MD||William Beaumont Hospitals|